Arcellx, Inc. (NASDAQ:ACLX) Shares Bought by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD grew its holdings in Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 11.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,121,322 shares of the company's stock after purchasing an additional 220,711 shares during the quarter. Price T Rowe Associates Inc. MD owned approximately 3.92% of Arcellx worth $162,685,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of ACLX. Gilead Sciences Inc. bought a new stake in Arcellx during the 4th quarter valued at $515,418,000. FMR LLC grew its stake in Arcellx by 22.8% in the fourth quarter. FMR LLC now owns 7,956,633 shares of the company's stock valued at $610,194,000 after purchasing an additional 1,477,360 shares during the last quarter. Vanguard Group Inc. raised its holdings in Arcellx by 35.3% in the fourth quarter. Vanguard Group Inc. now owns 3,330,092 shares of the company's stock worth $255,385,000 after purchasing an additional 867,996 shares in the last quarter. Capital World Investors bought a new position in Arcellx in the fourth quarter worth about $19,393,000. Finally, Dimensional Fund Advisors LP lifted its position in shares of Arcellx by 156.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 305,088 shares of the company's stock valued at $23,400,000 after buying an additional 186,013 shares during the last quarter. Hedge funds and other institutional investors own 96.03% of the company's stock.

Arcellx Trading Up 0.8 %

Shares of ACLX traded up $0.54 during midday trading on Friday, hitting $66.07. 111,471 shares of the company's stock traded hands, compared to its average volume of 551,907. The stock has a market capitalization of $3.64 billion, a price-to-earnings ratio of -93.00 and a beta of 0.33. Arcellx, Inc. has a 1 year low of $47.88 and a 1 year high of $107.37. The firm's fifty day moving average is $64.84 and its 200-day moving average is $74.22.

Arcellx (NASDAQ:ACLX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.24). Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. The company had revenue of $15.27 million for the quarter, compared to analysts' expectations of $27.42 million. On average, equities research analysts anticipate that Arcellx, Inc. will post -1.58 EPS for the current year.

Insider Buying and Selling

In other news, insider Rami Elghandour sold 38,300 shares of the stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $62.02, for a total transaction of $2,375,366.00. Following the transaction, the insider now owns 149,186 shares in the company, valued at $9,252,515.72. This trade represents a 20.43 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Kavita Patel sold 1,500 shares of the business's stock in a transaction that occurred on Tuesday, April 29th. The stock was sold at an average price of $64.20, for a total value of $96,300.00. The disclosure for this sale can be found here. Insiders have sold a total of 55,955 shares of company stock valued at $3,504,758 over the last ninety days. Company insiders own 6.24% of the company's stock.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).